Skip to main content
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Gain Therapeutics, Inc. - Common Stock (NQ:GANX)

2.080 +0.010 (+0.48%)
Streaming Delayed Price Updated: 4:00 PM EDT, Oct 9, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Gain Therapeutics, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 Next >
Gain Therapeutics to Host Virtual KOL Event on GT-02287 for Parkinson’s Disease
Event to be held October 14th at 4 p.m. EST 
From Gain Therapeutics, Inc.
Via GlobeNewswire
Gain Therapeutics Presents Initial Data from Phase 1b Clinical Study of GT-02287 in Parkinson’s Patients at International Congress of Parkinson’s Disease and Movement Disorders®
From Gain Therapeutics, Inc.
Via GlobeNewswire
Gain Therapeutics to Participate at Drug Discovery Innovation Programme 2025
From Gain Therapeutics, Inc.
Via GlobeNewswire
Gain Therapeutics Begins Its GT-02287 Phase 1b Extension Study in People with Parkinson’s Disease
From Gain Therapeutics, Inc.
Via GlobeNewswire
Gain Therapeutics Receives Australian Approval of Phase 1b Dosing Extension and Reports Positive Independent Data Monitoring Committee Recommendation
From Gain Therapeutics, Inc.
Via GlobeNewswire
Gain Therapeutics Reports Financial Results for Second Quarter 2025 and Provides Corporate Update
From Gain Therapeutics, Inc.
Via GlobeNewswire
12 Health Care Stocks Moving In Friday's After-Market Session
 
Via Benzinga
Gain Therapeutics to Present at BTIG Annual Virtual Biotechnology Conference
From Gain Therapeutics, Inc.
Via GlobeNewswire
Gain Therapeutics Announces Pricing of $7.0 Million Public Offering
From Gain Therapeutics, Inc.
Via GlobeNewswire
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
 
Via Benzinga
US Futures Trade Mixed As June Inflation Ticks Up: ASML, Morgan Stanley, Goldman Sachs, BofA Earnings In Focus
U.S. stock futures swung between gains and losses on Wednesday after ending on a mixed note on Tuesday. Futures of major benchmark indices were mixed. 
Via Benzinga
Topics Economy
Why Data Storage Shares Are Trading Higher By 35%; Here Are 20 Stocks Moving Premarket
 
Via Benzinga
12 Health Care Stocks Moving In Tuesday's After-Market Session
 
Via Benzinga
Tuesday's after hours session: top gainers and losers
The regular session of the US market on Tuesday is now over, but let's get a preview of the after-hours session and explore the top gainers and losers driving the post-market movements. 
Via Chartmill
Gain Therapeutics Announces Proposed Public Offering
From Gain Therapeutics, Inc.
Via GlobeNewswire
Gain Therapeutics Announces Completion of Target Enrollment in Phase 1b Clinical Study Evaluating GT-02287 in People With Parkinson’s Disease With or Without a GBA1 Mutation
From Gain Therapeutics, Inc.
Via GlobeNewswire
Gain Therapeutics to Participate in Upcoming Investor Conferences
From Gain Therapeutics, Inc.
Via GlobeNewswire
Gain Therapeutics Announces Oral Presentation at 2nd GBA1 Meeting
From Gain Therapeutics, Inc.
Via GlobeNewswire
Gain Therapeutics Reports Financial Results for First Quarter 2025 and Provides Corporate Update
First Biomarker Analysis from Phase 1b Study of GT-02287 in Parkinson’s Disease Expected Mid-2025 
From Gain Therapeutics, Inc.
Via GlobeNewswire
Gain Therapeutics Presents Preclinical Data at IAPRD 2025 30th World Congress on Parkinson’s Disease and Related Disorders
GT-02287 protects dopaminergic neurons against mitochondrial toxin MPP+ suggesting an action on mitochondrial GCase in addition to its improvement of lysosomal GCase activity 
From Gain Therapeutics, Inc.
Via GlobeNewswire
Gain Therapeutics to Participate at The Citizens Life Sciences Conference
From Gain Therapeutics, Inc.
Via GlobeNewswire
Gain Therapeutics Announces Oral Poster Presentation at IAPRD 2025 30th World Congress on Parkinson’s Disease and Related Disorders
From Gain Therapeutics, Inc.
Via GlobeNewswire
Gain Therapeutics Presents Additional Preclinical Data and Design of Phase 1b Clinical Study of GT-02287 at AD/PD 2025 and Provides Enrollment Update
From Gain Therapeutics, Inc.
Via GlobeNewswire
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
 
Via Benzinga
Gain Therapeutics Announces Poster Presentation at AD/PD 2025
From Gain Therapeutics, Inc.
Via GlobeNewswire
Gain Therapeutics Reports Financial Results for the Fourth Quarter and Year End 2024 and Provides Corporate Update
First Analysis from Phase 1b Study of GT-02287 in Parkinson’s Disease Expected in Q2 2025 
From Gain Therapeutics, Inc.
Via GlobeNewswire
Gain Therapeutics Doses First Participant in Phase 1b Clinical Trial of GT-02287 in Parkinson’s Disease
Via Get News
Gain Therapeutics Doses First Participant in Phase 1b Clinical Trial of GT-02287 in Parkinson's Disease
Via ACCESS Newswire
Gain Therapeutics Doses First Participant in Phase 1b Clinical Trial of GT-02287 in Parkinson’s Disease
Interim Analysis Expected End of 2Q 2025 
From Gain Therapeutics, Inc.
Via GlobeNewswire
Gain Therapeutics Announces Oral Presentation at AD/PD 2025
From Gain Therapeutics, Inc.
Via GlobeNewswire
< Previous 1 2 3 4 5 6 7 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.